Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States

Clinical Genitourinary Cancer

Volumn 14, Issue 5, 2016, Pages e479-e487

  Hackshaw, Michelle D ^a   Holmes, Michael ^a   Lankford, Maria ^b   Thomas, Michele ^b   Ogbonnaya, Augustina ^b   Eaddy, Michael ^b  

^a GLAXOSMITHKLINE   (United States)

^b XCENDA   (United States)

Author keywords

First line mRCC treatment; mRCC prescribing preferences; Pazopanib; Sunitinib; TKI

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; EVEROLIMUS; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PREFERENCE; DRUG TOLERABILITY; ELEVATED BLOOD PRESSURE; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPOTHYROIDISM; INTERNET; KIDNEY METASTASIS; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRESCRIPTION; PROGNOSTIC ASSESSMENT; PROGRESSION FREE SURVIVAL; UNITED STATES; CARCINOMA, RENAL CELL; CLINICAL PRACTICE; KIDNEY NEOPLASMS; METASTASIS; PRACTICE GUIDELINE; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; CARCINOMA, RENAL CELL; DRUG PRESCRIPTIONS; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; SULFONAMIDES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 84969523091     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2016.04.003     Document Type: Article

References (18)

1. 1 Rini, B.I., Campbell, S.C., Escudier, B., Renal cell carcinoma. Lancet 373 (2009), 1119–1132.
2. 2 Chow, W.H., Dong, L.M., Devesa, S.S., Epidemiology and risk factors for kidney cancer. Nat Rev Urol 7 (2010), 245–257.
3. 3 American Cancer Society: Cancer Facts and Figures 2016. Atlanta, Ga: American Cancer Society, 2016. Available at: http://www.cancer.org/acs/groups/cid/documents/webcontent/003107-pdf.pdf. Accessed: May 5, 2016.
4. 4 Motzer, R.J., New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overview. Oncologist 16:suppl 2 (2011), S1–S3.
5. 5 National Comprehensive Cancer Network (NCCN). Guidelines for kidney cancer, version 3.2015. Available at: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed: July 14, 2015.
6. 6 Ljungberg, B., Bensalah, K., Bex, A., et al. Renal cell carcinoma. Eur Assoc Urol, 2015 Available at: http://uroweb.org/guideline/renal-cell-carcinoma Accessed: July 14, 2015.
7. 7 Ryan, C.J., Second-line prescribing preferences (PPrefs) of US-based medical oncologists (MOs) following first-line TKI use in patients with metastatic clear cell renal cell carcinoma (mccRCC). J Clin Oncol, 32(suppl 4), 2014 abstract 492.
8. 8 Mekhail, T.M., Abou-Jawde, R.M., Boumerhi, G., et al. Validation and extension of the Memorial Sloan Kettering Prognostic Factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23 (2005), 832–841.
9. 9 Heng, D.Y., Xie, W., Regan, M.M., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27 (2009), 5794–5799.
10. 10 Motzer, R.J., Hutson, T.E., Tomczak, P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27 (2009), 3584–3590.
11. 11 Motzer, R.J., Hutson, T.E., Tomczak, P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007), 115–124.
12. 12 Sternberg, C.N., Davis, I.D., Mardiak, J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28 (2010), 1061–1068.
13. 13 Escudier, B., Bellmunt, J., Negrier, S., et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28 (2010), 2144–2150.
14. 14 Sternberg, C.N., Hawkins, R.E., Wagstaff, J., et al. A randomized, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 49 (2013), 1287–1296.
15. 15 Motzer, R.J., Hutson, T.E., Cella, D., et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369 (2013), 722–731.
16. 16 Escudier, B., Porta, C., Bono, P., et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol 32 (2014), 1412–1418.
17. 17 Vavallo, A., Simone, S., Lucarelli, G., et al. Preexisting type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma. Medicine 93 (2014), 1–7.
18. 18 Patel, H.D., Kates, M., Pierorazio, P.M., et al. Comorbidities and causes of death in the management of localized T1a kidney cancer. Int J Urol 21 (2014), 1086–1092.